Cancer Research Technology
Log in Register
Menu
Search
Monoclonal Antibodies

Anti-EGFR [EGFR1]

Invented by Dr Peter Goodfellow from Abingworth Life Sciences
Invented at Cancer Research UK London Research Institute: Lincoln's Inn Fields
  • Datasheet
  • Inventor Info
Print

Info

Catalogue Number 151090
Applications FACS IHC IF IP WB
Antigen/Gene or Protein Targets Epidermal Growth Factor Receptor (EGFR, Her1)
Reactivity Human
Relevance Monoclonal antibody which binds EGFR1 tyrosine kinase, commonly mutated in a range of cancers.

Background and Research Application
The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). EGFR activation signals multiple downstream signalling cascade pathways such as the Ras - ERK, PI3-K - Akt, Jak - STAT and PKC pathways which help in growth and proliferation of cells. Dysregulation of EGFR signalling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers, including head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, oesophagus, stomach and in squamous cell carcinoma. Tumours become dependent on EGFR signalling to maintain their malignant phenotypes.
Host Mouse
Immunogen Human epidermoid carcinoma line A431
Immunogen UniProt ID P00533
Subclass IgG2b kappa
Molecular Weight (kDa) 175
Myeloma Used P3/NS1/1-Ag4.1
Recommended Growing Conditions DMEM + 5% FCS
Strain Balb/c
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Anti-EGFR1 has no effect on tyrosine kinase activity of EGFR, and does not react with erbB-2, erbB-3 and erbB-4.

Concentration
1mg/ml as standard
Research Area Cancer, Cell Signaling & Signal Transduction

References

There are 13 reference entries for this reagent.

View All References

References: 13 entries

Finetti et al. 2015. Endocr Relat Cancer. 22(4):665-78. PMID: 26113609.

IHC

View  

Perillo et al. 2015. Nat Commun. 6:7874. PMID: 26219252.

View  

Tang et al. 2015. Oncol Rep. 34(1):350-8. PMID: 25955689.

IF WB

View  

mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.

Europe PMC ID: 26113609

View  

Downregulation of CD9 promotes pancreatic cancer growth and metastasis through upregulation of epidermal growth factor on the cell surface.

Europe PMC ID: 25955689

View  

Boersma et al. 2011. J Biol Chem. 286(48):41273-85. PMID: 21979953.

View  

Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.

Europe PMC ID: 21979953

View  

Jensen et al. 2006. Proc Natl Acad Sci U S A. 103(32):11958-63. PMID: 16877544.

View  

Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence.

Europe PMC ID: 16877544

View  

Gullick et al. 1986. Cancer Res. 46(1):285-92. PMID: 2998607.

View  

Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas.

Europe PMC ID: 2998607

View  

Waterfield et al. 1982. J Cell Biochem. 20(2):149-61. PMID: 6188757.

View  

A monoclonal antibody to the human epidermal growth factor receptor.

Europe PMC ID: 6188757

View  

Add a reference

References: 13 entries

Finetti et al. 2015. Endocr Relat Cancer. 22(4):665-78. PMID: 26113609.

IHC

View  

Perillo et al. 2015. Nat Commun. 6:7874. PMID: 26219252.

View  

Tang et al. 2015. Oncol Rep. 34(1):350-8. PMID: 25955689.

IF WB

View  

mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.

View  

Downregulation of CD9 promotes pancreatic cancer growth and metastasis through upregulation of epidermal growth factor on the cell surface.

View  

Boersma et al. 2011. J Biol Chem. 286(48):41273-85. PMID: 21979953.

View  

Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.

View  

Jensen et al. 2006. Proc Natl Acad Sci U S A. 103(32):11958-63. PMID: 16877544.

View  

Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence.

View  

Gullick et al. 1986. Cancer Res. 46(1):285-92. PMID: 2998607.

View  

Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas.

View  

Waterfield et al. 1982. J Cell Biochem. 20(2):149-61. PMID: 6188757.

View  

A monoclonal antibody to the human epidermal growth factor receptor.

View  

Add a reference

Inventor Information